DarioHealth Corp.

Personalized, Performance-based Healthcare

NASDAQ: DRIO

Forward Looking Statements

- This presentation of DarioHealth Corp. (the "Company") and statements of our management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate," "will," "would," and other similar expressions all denote forward-looking statements within the meaning of the Act.

- Readers are cautioned that actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. Factors that could cause or contribute to such differences include, but are not limited to our compliance with regulatory requirements, the impact of current and any future competition, our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise, our ability to manufacture, market and generate sales of our Dario™ diabetes management solution, as well as other factors and risks discussed in the Company's filings (including the results of the company's commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

- In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by our management or agents have been prepared by our management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to our future performance. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles.

DarioHealth | Investment Highlights

Strong **revenue growth – 60%-80% year over year**

Ready to mass market – Post R&D, Regulation phase

Large and growing **global market opportunity**

User-centric, data-driven **scalable Platform**

DarioHealth | Industry Leader in Digital Health Ecosystem

Top Ten Reviews

DarioHealth's Dario Blood Glucose Monitoring System was voted as the **Best Glucometer for Data Management** by Top Ten Reviews.

Global Digital Health 100

An international benchmark of innovation in the healthcare technology industry recognizes DarioHealth as a leader and supports health technology companies that are demonstrating **the greatest potential to change the way that healthcare is delivered.**

Philips HighTechXL

DarioHealth was selected in 2017 by HighTechXL, for its strong management team, innovative business model, and smart solutions for diabetes management.

DarioHealth | Geographical Market Overview

425m

People with diabetes (2017)

693m

People with diabetes projected by 2045

471m

Pre-diabetes projected by 2035*

* Prediabetes diagnosis and treatment: A review, by Nihdi Bansal, 15 Mar 2015

Dario currently has access to

48.5 million people with diabetes worldwide



UK	Australia	Canada	Italy	USA	Netherlands	Germany
Since Q1 2015 Insurance Coverage	Since Q3 2015 Insurance Coverage	Since Q4 2015 Insurance Coverage	Since Q1 2016 Insurance Coverage	Since Q2 2016 Partial Coverage	Since Q3 2016 Insurance Coverage	Since Q3 2017
2.7m	1.1m	2.6m	3.4m	30.2m	1.0m	7.5m

Population with Diabetes by Country

DarioHealth | At a Glance

2011
Founded

New York and Israel
Global presence

48
Employees

7
Countries with users

4
Regulatory bodies approvals/clearance

5
Countries fully reimbursed

$5.2m
2017 Revenue

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease treatment, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down.

Yearly Revenue



DarioHealth | From Generic Traditional to Personal performance-based Healthcare

Traditional

- **Periodic** data
- **General statistics** based treatment
- **Independent factors** - silo events
- **Driven by theories** & independent professionals

DarioHealth

- **Real-time** streamed data
- **Personalized performance-based** treatment
- **Dependency reaction** of events
- **Driven by personalized data** & AI/ML technology

Dario Savings

Studies have shown that Dario's **1% reduction in HbA1c** yields substantial savings

$80 - $100 per patient per month.

$35.8 billion of potential savings to the U.S. healthcare system

DarioHealth | End to End Holistic Solution

Dario Cloud

Big data and smart analytics for personalized plans with SMART goals, real-time alerts, dashboard and trends

My Dario

The original, all-in-one smart blood glucose management system: device, Native mobile management app and unlimited strip supplies

Dario Engage

Scalable engagement platform to monitor, coach, and manage diabetes population

DarioHealth | Everybody Wins

User-centric, personalized health

over 30,000 active users are sending us amazing feedback

High-Rated

App in App store and Google Play

Improved Clinical Outcomes

1% Reduction

of HbA1C

Minimizing Healthcare Costs

Saving $80-$100

per patient per month

DarioHealth | The Dario Engage Platform

Monitoring

Coaching



Management

Engagement

Dario Engage Platform provides full coverage, scalable healthcare solutions that are easily customized to integrate with any clinical programs covering all facets of diabetes management and care:
Type1, Type2, gestational diabetes, and prediabetes.

DarioHealth | Competitive Landscape

DarioHealth is the only **comprehensive** diabetes management platform

More Users

- Expend into more territories
- Utilize more channels (Payers, Clinics, Employers)
- Supporting other disease states

More Revenue per user

- Device and disposables
- In-app premium & membership offers
- Payed professional services (coaching, dietitians, endocrinologists)

DarioHealth | Recent News

DarioHealth | Executive Team

An experienced management team with vast software, medical device and technology experience guided by a world class Board Of Directors and Scientific Advisory Board.

Erez Raphael | CEO & Chairman

Mr. Raphael has over 20 years of systems and software development experience in various industries including mobile, life science, medical device, health IT, mHealth and digital health solutions.

Dror Bacher | COO

Mr. Bacher has more than 17 years of software business experience, including managing positions in product development at both mobile and semi-conductor companies. Previously, he held numerous executive positions, including a leadership role at Amdocs, managing enterprise development programs.

João Mendes-Roter | VP Marketing

With over 20 years of experience, Ms. Mendes-Roter is a marketing executive and online digital expert in growth marketing and direct response. She has a proven track-record in increasing revenues and costumer experience, via better funnels, new products, effective online-offline marketing channels, and new business opportunities. Prior to joining DarioHealth, she held senior roles at 888 Holdings and gained valuable experience at RadView Software and Dun & Bradstreet.

Yinon Amir | Head of Software

Mr. Amir brings vast experience in software development, engineering practices, digital technologies, solution architecture and design, as well as large scale projects management and customer delivery management. Previously, he held senior management positions at Amdocs, a global leader in telecommunications customer experience and billing solutions.

Shmuel Herschberg | Director, Marketing and User Engagement

Mr. Herschberg is a seasoned digital marketing executive with over 18 years of experience. He possesses a unique blend of technical understanding coupled with a flair for creativity, strategic thinking, and customer psychology. Previously he held a senior position at an interactive, direct-to-consumer marketing company where he was responsible for creating successful revenue streams.

Zvi Ben-David | CFO

Mr. Ben-David has 25 years of financial and accounting experience, particularly with medical device companies. Among his previous roles, he served as Corporate VP & CFO of Given Imaging, where he was a part of the founding team and also helped lead the start-up to a $65 million annual revenue commercial enterprise as well as its successful initial and follow-on public offerings.

Adiel Levin | Global Senior Director, Sales and Commercialization

Mr. Levin has 20+ years of channel sales, business development, strategy and leadership experience in the telecommunications, financial services and health sectors, in both B2B and B2C. He has managed global sales teams, channel partners and distribution networks in the EMEA and APAC regions for telecom, healthcare and financial services industries.

Olivier Jarry | Strategic Advisor

Mr. Jarry has managed innovation at the crossroads of technology, healthcare and patient-centricity for three decades on five continents. He has had several executive roles in life sciences multinationals such as leading the global Diabetes Care division of Bayer.

Janice Baker | RDN, CDE

Janice Baker has been providing diet counseling and medical nutrition therapy since 1982, specializing in weight management, diabetes education, and cardiac risk reduction. A graduate of California Polytechnic State University, San Luis Obispo, Good Samaritan Hospital Internship, and National University, Janice also holds a Master's Degree in Business Administration as well as a Bachelor of Science Degree in Dietetics and Food Administration. She is a Certified Nutrition Support Dietitian and has been a Certified Diabetes Educator since 1992. In 2012, Janice became Board Certified in Advanced Diabetes Management.

Financial Review

DarioHealth | Financial Highlights

- Subscription model yields highly recurring and visible revenues
  - 62% users under recurring plans
- Service is becoming an increasing contributor to revenues
- Diversified revenue streams
- Scalable model with meaningful operating leverage
- Recently launched B2B (employers) strategy provides incremental market opportunity and growth

DarioHealth | Quarterly Revenue

Consistent Revenue Growth



- Gradually improving contribution and Gross Profit
- Service revenue expected to:
  - Accelerate Gross Profit improvement
  - Improve net profit % of sales
- Record revenues of $5.2m in 2017, increase of 84% compared to the full year 2016
- 12 consecutive quarters of revenue growth

DarioHealth | Increase Revenue per Member Over Time



DarioHealth | Diversified Revenue Streams

Revenue by Region - Q1:Q4 2017



Subscriptions Vs. One Time - 2017



DarioHealth | U.S. Market Potential in Long-Term Lookout



Users

Revenue

250k = $100m

With Growth Forecast of 1% market penetration in the US only:

Users

Revenue

400k = $160m

DarioHealth | Stronger Capitalization Well Positioned to Support Growth

Capitalization Transformation

	March 20, 2018
Shares Outstanding	16,447,914
C preferred as converted	2,468,160
Warrants Outstanding	7,265,868
ESOP	2,516,414
Affiliates, directors and officers beneficial ownership	27.7%
Debt	---

Capitalization Highlights

- Major shareholders and insiders – 53.1%
- 22.3% Held by institutions.
- 7.8% is held by board members and management.
- Insider Transactions - Board and Management invested so far more then $3M into the company.

DarioHealth | Contact Information

Commercial Office

142 W 57th Street
8th Floor
New York, NY 10019
USA
partnershipgroup@dariohealth.com
www.dariohealth.com

R&D Center

8 Hatokhen Street
North Industrial Park
Caesarea 389000
Israel

Investor Relations

Westwicke Partners
Tel: 1-443-213-0500
Dario@Westwicke.com